(Note: For PDF File Swipe To The End Of Article)
Asthma is a chronic respiratory disease characterized by variable respiratory symptoms and variable expiratory airflow limitation. It is associated with airway inflammation, bronchial hyperresponsiveness, and episodes of airway narrowing that can cause wheezing, cough, chest tightness, and shortness of breath.
The treatment of asthma is not based on a single medication. Different drugs target different parts of the disease process. Some medicines rapidly relax airway smooth muscle, while others suppress airway inflammation and reduce the risk of future exacerbations. In patients with severe asthma, biologic therapies can target specific inflammatory pathways.
The 2026 Global Initiative for Asthma (GINA) strategy continues to emphasize treatment containing an inhaled corticosteroid (ICS), rather than relying on a short-acting bronchodilator alone. GINA's 2026 report is the current major international reference for asthma management.
Medical disclaimer: This article is intended for educational purposes, particularly for medical, pharmacy, nursing, and healthcare students. It does not replace a clinician's assessment or an individualized asthma action plan. Medication choice and dosing depend on age, severity, phenotype, comorbidities, inhaler device, local guidelines, and the patient's response to treatment.
What Is Asthma?
Asthma is a chronic inflammatory disorder of the airways in which symptoms and airflow limitation can vary over time.
Typical symptoms include:
- Wheezing
- Shortness of breath
- Chest tightness
- Cough
- Nocturnal or early-morning symptoms
- Exercise-related breathing difficulty
- Symptoms triggered by allergens, infections, smoke, cold air, or other exposures
Three important processes contribute to asthma:
1. Airway inflammation
Inflammatory cells and mediators contribute to swelling and increased sensitivity of the bronchial tree.
2. Bronchoconstriction
Airway smooth muscle contracts, narrowing the bronchial lumen.
3. Airway hyperresponsiveness
The airways become excessively reactive to various stimuli.
This explains why asthma treatment generally requires both:
Bronchodilation + control of airway inflammation
Why Are Drugs Used in Asthma?
Asthma medicines have several different objectives.
They may be used to:
- Quickly relieve bronchoconstriction
- Reduce airway inflammation
- Prevent asthma symptoms
- Prevent exacerbations
- Improve lung function
- Reduce nighttime symptoms
- Improve exercise tolerance
- Reduce hospitalizations
- Reduce the need for systemic corticosteroids
- Control severe asthma
- Target specific inflammatory pathways
A key pharmacological principle is that symptom relief and disease modification are not necessarily the same thing.
For example, a bronchodilator can rapidly improve airflow, but an inhaled corticosteroid addresses airway inflammation and helps reduce future exacerbation risk.
Classification of Drugs Used in Asthma
Asthma medications can broadly be divided into several groups.
| Drug class | Examples | Main role |
|---|---|---|
| Short-acting β₂ agonists | Salbutamol/albuterol | Rapid bronchodilation |
| Inhaled corticosteroids | Budesonide, beclometasone, fluticasone | Anti-inflammatory controller |
| ICS-formoterol | Budesonide-formoterol | Reliever and/or controller depending on regimen |
| Long-acting β₂ agonists | Formoterol, salmeterol | Long-term bronchodilation with ICS |
| LAMA | Tiotropium | Add-on bronchodilation |
| Leukotriene modifiers | Montelukast, zafirlukast | Anti-leukotriene therapy |
| Systemic corticosteroids | Prednisolone, prednisone, methylprednisolone | Severe exacerbations/selected severe disease |
| Methylxanthines | Theophylline | Limited/alternative role |
| Biologics | Omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab | Severe asthma phenotypes |
| Anticholinergic bronchodilator | Ipratropium | Mainly acute severe exacerbations |
| IV magnesium sulfate | Magnesium sulfate | Selected severe exacerbations |
1. Short-Acting β₂ Agonists — SABA
One of the best-known asthma medications is salbutamol, also called albuterol in the United States.
Other examples and related drugs include:
- Salbutamol/albuterol
- Terbutaline in some settings
These medications are known as short-acting β₂ agonists (SABAs).
Mechanism of Action
SABAs stimulate β₂-adrenergic receptors on bronchial smooth muscle.
This activates adenylate cyclase:
β₂ receptor stimulation → ↑ cAMP → smooth-muscle relaxation → bronchodilation
The result is widening of the airways and improved airflow.
Clinical Effect
SABAs generally act rapidly and are useful for relieving acute bronchoconstriction.
They can improve:
- Wheezing
- Chest tightness
- Shortness of breath
- Airflow limitation
However, an important modern asthma-management principle is that SABA should not be used as the only asthma treatment in adults and adolescents. GINA recommends ICS-containing treatment because asthma inflammation needs to be addressed, not simply the bronchoconstriction.
Adverse Effects of SABA
Because β₂ agonists can have systemic effects, excessive use may cause:
- Tremor
- Palpitations
- Tachycardia
- Headache
- Anxiety or nervousness
- Muscle cramps
- Hypokalemia, particularly with high doses
Frequent SABA use can also be a warning sign that asthma is inadequately controlled.
Important exam point
Salbutamol relaxes bronchial smooth muscle but does not provide the anti-inflammatory control supplied by ICS therapy.
2. Inhaled Corticosteroids — ICS
Inhaled corticosteroids are among the most important controller medications in asthma.
Common examples include:
- Budesonide
- Beclometasone
- Fluticasone propionate
- Fluticasone furoate
- Mometasone
- Ciclesonide
ICS medications reduce airway inflammation and are fundamental to long-term asthma management.
Mechanism of Inhaled Corticosteroids
Corticosteroids enter airway cells and bind to intracellular glucocorticoid receptors.
The drug-receptor complex influences gene transcription and modifies inflammatory mediator production.
This produces several effects:
- Reduced airway inflammation
- Reduced inflammatory-cell activity
- Reduced airway hyperresponsiveness
- Reduced mucosal edema
- Reduced mucus production
- Improved response to β₂ agonists
- Reduced risk of asthma exacerbations
The important concept is:
ICS = anti-inflammatory control
whereas:
SABA = rapid bronchodilation
Why Are ICS Drugs So Important?
Asthma may feel like a problem of bronchospasm because patients experience sudden narrowing of the airways. However, underlying airway inflammation is a major component of the disease.
Therefore, repeatedly treating symptoms with a bronchodilator without addressing inflammation is inadequate asthma management.
GINA's current strategy emphasizes ICS-containing therapy and recommends against SABA-only treatment for adults and adolescents.
Adverse Effects of Inhaled Corticosteroids
ICS therapy is generally much more targeted than systemic corticosteroid therapy, but adverse effects can occur.
Common local effects include:
- Oral candidiasis
- Dysphonia/hoarseness
- Throat irritation
- Cough
The risk can be reduced by:
- Using an appropriate inhaler technique
- Using a spacer with suitable pressurized metered-dose inhalers
- Rinsing the mouth after use
At higher doses and with prolonged exposure, systemic corticosteroid effects become more relevant.
These may include:
- Adrenal suppression
- Osteoporosis
- Cataracts
- Glaucoma
- Skin thinning
The goal is therefore to use the lowest effective ICS-containing regimen that maintains good asthma control, with regular reassessment.
3. ICS-Formoterol
One of the most important developments in modern asthma pharmacology is the use of ICS-formoterol.
A commonly known combination is:
Budesonide + formoterol
Other ICS-formoterol products exist depending on country and regulatory approval.
This combination is particularly important because:
- ICS provides anti-inflammatory treatment.
- Formoterol provides bronchodilation.
- Formoterol has a rapid onset suitable for reliever use.
This allows the same medication combination to provide both symptom relief and anti-inflammatory treatment in appropriate regimens.
What Is MART?
MART means:
Maintenance-and-Reliever Therapy
The patient uses an ICS-formoterol inhaler for regular maintenance doses and also uses the same type of inhaler when symptoms occur.
This can simplify treatment because one inhaler can serve both purposes.
GINA's current strategy uses ICS-formoterol in its preferred treatment track for appropriate patients, including as-needed low-dose ICS-formoterol at the lower treatment steps and maintenance-and-reliever therapy at higher steps.
Why Is ICS-Formoterol Different From SABA Alone?
Consider two approaches.
Approach A
Patient experiences symptoms → uses SABA.
The patient receives bronchodilation.
Approach B
Patient experiences symptoms → uses an appropriate ICS-formoterol reliever.
The patient receives:
Bronchodilation + inhaled corticosteroid
Therefore, the second approach can simultaneously address symptoms and airway inflammation.
The exact regimen depends on the patient's age, treatment step, inhaler strength, local availability, and clinician's instructions.
4. Long-Acting β₂ Agonists — LABA
Long-acting β₂ agonists provide prolonged bronchodilation.
Examples include:
- Formoterol
- Salmeterol
- Vilanterol
- Other LABAs depending on the formulation and country
Mechanism
LABAs stimulate β₂ receptors and increase intracellular cAMP, producing prolonged relaxation of bronchial smooth muscle.
LABA Should Not Be Used Alone in Asthma
This is one of the most important pharmacology points.
LABA monotherapy is not appropriate for asthma.
Instead, LABA is generally used together with an ICS.
Examples include:
- Budesonide-formoterol
- Fluticasone-salmeterol
- Mometasone-formoterol
- Fluticasone-vilanterol
The principle is:
ICS controls inflammation + LABA provides prolonged bronchodilation
Formoterol vs Salmeterol
Both are LABAs, but they differ pharmacologically.
Formoterol has a relatively rapid onset of bronchodilation and can therefore be used in appropriate ICS-formoterol reliever regimens.
Salmeterol has a slower onset and is generally used as a maintenance bronchodilator rather than as a rapid reliever.
Exam pearl
If asked which LABA is associated with rapid onset and ICS-formoterol reliever strategies:
Formoterol
5. ICS/LABA Combination Inhalers
Combining an inhaled corticosteroid with a LABA is a central approach to long-term asthma treatment.
Common examples include:
Budesonide + formoterol
Provides:
- Anti-inflammatory effect
- Long-acting bronchodilation
- Rapid bronchodilation from formoterol
Fluticasone + salmeterol
Provides:
- Anti-inflammatory action
- Long-acting bronchodilation
Mometasone + formoterol
Another ICS/LABA combination used in appropriate patients.
Fluticasone furoate + vilanterol
Provides once-daily maintenance treatment in appropriate formulations.
The exact indication and dosing depend on the product's regulatory approval.
6. Long-Acting Muscarinic Antagonists — LAMA
LAMA means:
Long-Acting Muscarinic Antagonist
The major example used as an asthma add-on is:
Tiotropium
Some triple inhalers also contain an ICS, LABA, and LAMA.
Mechanism of Tiotropium
Parasympathetic stimulation of airway muscarinic receptors promotes bronchoconstriction.
Tiotropium blocks muscarinic receptors, reducing cholinergic bronchoconstriction.
Therefore:
Muscarinic blockade → reduced bronchoconstriction → improved airway caliber
When Is LAMA Used?
LAMA is generally considered an add-on therapy rather than the first medication used for ordinary asthma.
GINA 2026 describes LAMA options such as adding tiotropium to ICS-LABA or using appropriate triple inhaler therapy in selected patients whose asthma remains uncontrolled.
Importantly, before simply adding another bronchodilator, clinicians should reassess:
- Inhaler technique
- Adherence
- Exposure to triggers
- Comorbidities
- Diagnosis
- Adequacy of ICS therapy
7. Leukotriene Modifiers
Leukotrienes are inflammatory mediators involved in bronchoconstriction, mucus production, vascular permeability, and airway inflammation.
Drugs that modify leukotriene pathways include:
- Montelukast
- Zafirlukast
Montelukast is the most commonly recognized example.
Montelukast
Montelukast is a:
Leukotriene receptor antagonist
It blocks the cysteinyl leukotriene CysLT₁ receptor.
This reduces the effects of leukotrienes on the airways.
Potential benefits include reduction in:
- Bronchoconstriction
- Airway edema
- Mucus production
- Airway inflammatory responses
When Can Montelukast Be Useful?
Montelukast may be considered in selected patients, including some patients with:
- Asthma associated with allergic rhinitis
- Exercise-induced bronchoconstriction
- Patients who have difficulty using inhaled medications
- Selected patients as an alternative or add-on treatment
However, it is generally not considered equivalent to ICS as the main anti-inflammatory treatment for most patients.
Important Montelukast Safety Warning
Montelukast deserves special attention because the FDA requires a Boxed Warning concerning serious neuropsychiatric adverse effects.
Reported events include:
- Mood changes
- Behavioral changes
- Sleep disturbances
- Depression
- Suicidal thoughts or behavior
The FDA recommends discussing the benefits and risks before prescribing montelukast and monitoring patients for neuropsychiatric symptoms.
Important exam point
Montelukast → leukotriene receptor antagonist → useful in selected asthma patients, but remember the neuropsychiatric warning.
8. Systemic Corticosteroids
Systemic corticosteroids are extremely important in the management of moderate-to-severe asthma exacerbations.
Examples include:
- Prednisolone
- Prednisone
- Methylprednisolone
- Hydrocortisone
They can be given orally or intravenously depending on the clinical situation.
Mechanism of Systemic Corticosteroids
Like ICS, systemic corticosteroids suppress inflammatory pathways.
They reduce:
- Airway inflammation
- Mucosal edema
- Inflammatory mediator production
- Airway hyperresponsiveness
Their effects are broader than those of inhaled corticosteroids because the medication acts throughout the body.
When Are Oral Corticosteroids Used?
Short courses may be required during significant exacerbations.
They are particularly important when:
- Symptoms are rapidly worsening
- Reliever therapy is not adequately controlling symptoms
- Lung function is substantially reduced
- The patient has a history of severe exacerbations
- Emergency treatment is required
The exact dose and duration depend on the patient's age, severity, and guideline.
Problems With Repeated Oral Steroid Use
Systemic corticosteroids can be life-saving during severe exacerbations, but repeated courses are associated with cumulative harm.
Potential adverse effects include:
- Hyperglycemia
- Hypertension
- Weight gain
- Mood changes
- Insomnia
- Fluid retention
- Osteoporosis
- Cataracts
- Adrenal suppression
- Increased infection risk
Therefore, modern asthma management aims to reduce the need for repeated systemic corticosteroid courses through effective controller treatment.
9. Ipratropium
Ipratropium is a:
Short-acting muscarinic antagonist — SAMA
It blocks muscarinic receptors and produces bronchodilation.
Unlike salbutamol, it does not stimulate β₂ receptors.
Role of Ipratropium in Asthma
Ipratropium is not usually the primary long-term asthma medication.
It has an important role as an add-on bronchodilator during severe acute asthma exacerbations.
It may be combined with a SABA in emergency treatment.
The mechanism is complementary:
SABA → β₂ stimulation
Ipratropium → muscarinic blockade
Together they can produce greater bronchodilation during severe attacks.
10. Magnesium Sulfate
Magnesium sulfate is not a routine daily asthma medicine.
It may be considered in selected patients with severe acute asthma who have inadequate response to initial therapy.
It is generally administered intravenously in an emergency setting.
Its exact bronchodilatory mechanism is not completely understood, but it can promote smooth-muscle relaxation.
Important point
IV magnesium sulfate is an adjunct in selected severe exacerbations — not a routine controller medication.
11. Theophylline
Theophylline is a methylxanthine bronchodilator.
Historically, it was used much more frequently in asthma.
Its use has declined because it has:
- A narrow therapeutic window
- Numerous drug interactions
- Variable pharmacokinetics
- Significant adverse effects
Mechanism of Theophylline
Theophylline has several pharmacological actions, including phosphodiesterase inhibition and antagonism of adenosine receptors.
The result can include:
↑ intracellular cAMP → bronchodilation
However, its therapeutic margin is narrow.
Adverse Effects of Theophylline
Toxicity can cause:
- Nausea
- Vomiting
- Tremor
- Headache
- Palpitations
- Tachycardia
- Arrhythmias
- Insomnia
- Seizures
Severe toxicity can be life-threatening.
For this reason, theophylline is not a preferred modern asthma medication when safer and more effective options are available.
12. Biologic Drugs for Severe Asthma
Biologic therapy has transformed the treatment of some patients with severe asthma.
These medications target specific molecules or pathways involved in asthma inflammation.
They are generally used in patients with severe asthma that remains uncontrolled despite optimized inhaled therapy.
GINA 2026 lists several biologic classes for appropriately selected patients.
Major Asthma Biologics
Important examples include:
- Omalizumab
- Mepolizumab
- Benralizumab
- Reslizumab
- Dupilumab
- Tezepelumab
- Depemokimab in appropriate settings
These drugs are not interchangeable.
The choice depends on factors such as:
- Asthma phenotype
- IgE level
- Sensitization
- Blood eosinophils
- Exacerbation history
- Type 2 inflammation
- Dependence on systemic corticosteroids
- Age
- Regulatory approval
13. Omalizumab
Omalizumab is an:
Anti-IgE monoclonal antibody
It is used in appropriately selected patients with severe allergic asthma.
Mechanism of Omalizumab
Omalizumab binds circulating IgE.
This reduces the availability of free IgE and interferes with IgE-mediated allergic inflammatory pathways.
The simplified pathway is:
Allergen → IgE-mediated response → mast-cell activation → inflammatory mediators
Omalizumab reduces the IgE component of this pathway.
GINA 2026 lists anti-IgE therapy such as subcutaneous omalizumab for appropriately selected patients with severe allergic asthma.
14. Mepolizumab
Mepolizumab is an:
Anti-IL-5 monoclonal antibody
It is used for selected patients with severe eosinophilic asthma.
IL-5 is important for eosinophil growth, maturation, activation, and survival.
Blocking IL-5 can therefore reduce eosinophilic inflammation.
15. Benralizumab
Benralizumab targets:
IL-5 receptor alpha
It is used in selected patients with severe eosinophilic asthma.
Its mechanism results in marked reduction of eosinophils through antibody-dependent cellular cytotoxicity.
16. Reslizumab
Reslizumab is another:
Anti-IL-5 therapy
It is used for selected severe eosinophilic asthma patients.
Unlike several subcutaneous biologics, reslizumab is administered intravenously.
17. Dupilumab
Dupilumab blocks:
IL-4 receptor alpha
This interferes with signaling involving both:
- IL-4
- IL-13
These cytokines are important components of Type 2 inflammation.
GINA 2026 includes dupilumab as an add-on option for appropriately selected patients with severe Type 2/eosinophilic asthma and for some patients requiring maintenance oral corticosteroids.
18. Tezepelumab
Tezepelumab is an:
Anti-TSLP monoclonal antibody
TSLP is an epithelial-derived cytokine involved early in airway inflammatory signaling.
Because TSLP is positioned relatively high in the inflammatory cascade, blocking it can influence multiple downstream inflammatory pathways.
GINA 2026 includes tezepelumab as an option for appropriately selected patients with severe asthma.
19. Depemokimab
Depemokimab is an anti-IL-5 therapy included in the current GINA 2026 severe-asthma treatment landscape for selected patients.
Its inclusion illustrates an important development in asthma pharmacology:
Biologic therapy is becoming increasingly targeted toward specific inflammatory pathways and patient phenotypes.
Biologics Are Not Rescue Drugs
This is extremely important.
Biologic medications are not designed to immediately relieve an acute asthma attack.
A patient experiencing acute severe bronchospasm requires appropriate emergency treatment.
Think of biologics as:
Long-term targeted disease-modifying therapy
not:
Rapid bronchodilator therapy
20. Triple Inhaler Therapy
Some patients with difficult-to-control asthma may receive:
ICS + LABA + LAMA
This is called triple inhaled therapy.
Examples of components include:
- ICS
- LABA
- LAMA
GINA 2026 lists several triple-inhaler options and also describes separate tiotropium as an add-on to ICS-LABA in appropriate patients.
Adding LAMA to ICS-LABA produces a relatively modest improvement in lung function, while evidence suggests a reduction in severe exacerbation risk in selected populations.
21. What Happens During an Acute Asthma Exacerbation?
An asthma exacerbation involves worsening respiratory symptoms and airflow limitation.
The patient may develop:
- Increasing wheezing
- Severe breathlessness
- Difficulty speaking
- Chest tightness
- Tachypnea
- Reduced oxygen saturation
- Reduced peak expiratory flow
- Use of accessory muscles
Severe attacks can become life-threatening.
Drugs Used in Acute Asthma
Treatment may involve several medications depending on severity.
Rapid bronchodilator
A SABA such as salbutamol/albuterol is commonly used.
Ipratropium
Added particularly in severe exacerbations.
Systemic corticosteroid
Oral or intravenous corticosteroid therapy may be required.
Oxygen
Supplemental oxygen is used when clinically indicated.
Magnesium sulfate
May be considered in selected severe attacks that do not respond adequately to initial treatment.
The exact emergency regimen must follow current local protocols and clinical assessment.
Why Is Salbutamol Not Enough During a Severe Attack?
Salbutamol can produce powerful bronchodilation, but the inflammatory component of an exacerbation also needs treatment.
Therefore, severe exacerbation management often combines:
Bronchodilation + anti-inflammatory therapy + supportive care
This explains the importance of systemic corticosteroids during significant exacerbations.
22. Stepwise Asthma Treatment
Asthma treatment is generally adjusted according to:
- Symptom control
- Exacerbation risk
- Lung function
- Adherence
- Inhaler technique
- Comorbidities
- Treatment response
GINA's preferred adult/adolescent strategy uses ICS-formoterol-containing treatment in appropriate patients, including as-needed use at lower treatment steps and maintenance-and-reliever therapy at higher steps.
Simplified Treatment Concept
Lower treatment needs
Appropriate patients may use:
As-needed low-dose ICS-formoterol
rather than relying on SABA alone.
Increasing symptoms or exacerbation risk
Treatment may progress to:
Maintenance ICS-formoterol + reliever ICS-formoterol
using the MART approach.
Persistent uncontrolled asthma
Higher-dose ICS-containing therapy and additional options may be considered.
Severe asthma
Specialist assessment may lead to:
- LAMA
- Triple therapy
- Biologics
- Other selected add-on therapies
23. Why SABA Overuse Is a Warning Sign
A patient who repeatedly needs a rescue inhaler may think:
"My asthma medicine is working because the inhaler relieves my symptoms."
But frequent reliance on a reliever can indicate that the underlying asthma is poorly controlled.
Potential reasons include:
- Inadequate controller therapy
- Poor inhaler technique
- Poor adherence
- Persistent trigger exposure
- Incorrect diagnosis
- Comorbid disease
- Severe asthma phenotype
Therefore, frequent reliever use should trigger reassessment rather than simply repeated prescriptions.
24. Inhaler Technique Is Part of Pharmacology
Even an excellent medication cannot work properly if it does not reach the lungs.
Common inhaler errors include:
- Incorrect inhalation speed
- Poor coordination
- Failure to hold the breath when appropriate
- Failure to prime the device
- Incorrect loading of a dry-powder inhaler
- Not using a spacer when indicated
- Not completing the prescribed inhalation steps
Before escalating therapy, clinicians should verify technique.
Spacer Devices
A spacer can improve drug delivery from many pressurized metered-dose inhalers.
It can also reduce oropharyngeal deposition of inhaled corticosteroids.
For some patients, correct use of a spacer can make a major difference.
25. Asthma Drugs and Their Main Mechanisms
| Drug | Main mechanism | Main effect |
|---|---|---|
| Salbutamol | β₂ agonist | Rapid bronchodilation |
| Formoterol | Long-acting β₂ agonist | Prolonged bronchodilation |
| Salmeterol | Long-acting β₂ agonist | Prolonged bronchodilation |
| Budesonide | Corticosteroid | Anti-inflammatory |
| Fluticasone | Corticosteroid | Anti-inflammatory |
| Tiotropium | Muscarinic antagonist | Bronchodilation |
| Ipratropium | Muscarinic antagonist | Bronchodilation |
| Montelukast | CysLT₁ receptor antagonist | Reduces leukotriene effects |
| Theophylline | Methylxanthine | Bronchodilation |
| Omalizumab | Anti-IgE | Reduces allergic inflammation |
| Mepolizumab | Anti-IL-5 | Reduces eosinophilic inflammation |
| Benralizumab | Anti-IL-5Rα | Depletes eosinophils |
| Dupilumab | IL-4Rα blockade | Reduces Type 2 inflammation |
| Tezepelumab | Anti-TSLP | Reduces upstream inflammatory signaling |
26. Common Adverse Effects: Quick Review
| Drug/class | Important adverse effects |
|---|---|
| SABA | Tremor, tachycardia, palpitations, hypokalemia |
| LABA | Tremor, tachycardia, palpitations |
| ICS | Oral candidiasis, dysphonia |
| Systemic steroids | Hyperglycemia, hypertension, osteoporosis, infection risk |
| Montelukast | Neuropsychiatric effects |
| Theophylline | GI effects, arrhythmias, seizures in toxicity |
| Ipratropium | Dry mouth, anticholinergic effects |
| Tiotropium | Dry mouth, anticholinergic effects |
| Biologics | Injection/infusion reactions and agent-specific adverse effects |
27. Asthma Drugs: Reliever vs Controller
One of the easiest ways to understand asthma pharmacology is to divide drugs by their purpose.
Reliever-oriented therapy
Designed to provide rapid relief of bronchoconstriction.
Examples include:
- SABA
- Appropriate ICS-formoterol regimens
Controller therapy
Designed to reduce inflammation and future risk.
Examples include:
- ICS
- ICS/LABA
- ICS-formoterol maintenance therapy
- Selected LAMA add-on therapy
- Leukotriene modifiers in selected patients
- Biologic therapy for severe asthma
Exacerbation treatment
Examples include:
- Repeated rapid bronchodilator therapy
- Ipratropium in severe exacerbations
- Systemic corticosteroids
- Oxygen when indicated
- IV magnesium sulfate in selected severe cases
28. Which Asthma Drug Is Best for Allergic Asthma?
There is no single answer for every patient.
Treatment depends on severity and phenotype.
ICS-containing therapy remains foundational.
For selected patients with severe allergic asthma despite optimized treatment, omalizumab may be considered.
The decision depends on clinical characteristics, biomarkers, exacerbation history, age, and regulatory eligibility.
29. Which Drug Is Used for Eosinophilic Asthma?
Several biologics target eosinophilic inflammation.
Examples include:
- Mepolizumab
- Benralizumab
- Reslizumab
- Dupilumab in appropriate Type 2/eosinophilic asthma
- Depemokimab in appropriate patients
The choice depends on the specific patient profile.
30. Asthma With Allergic Rhinitis
Asthma and allergic rhinitis frequently coexist.
A patient may have:
- Nasal congestion
- Sneezing
- Rhinorrhea
- Itchy eyes
- Wheezing
- Cough
Treating upper-airway disease can be part of comprehensive respiratory management.
Montelukast may have a role in selected patients, but its neuropsychiatric warning must be considered.
31. Asthma and Exercise
Exercise can trigger bronchoconstriction in some patients.
The management strategy depends on baseline asthma control.
Poorly controlled asthma should not simply be treated by repeatedly taking a reliever before every activity.
The underlying asthma should be appropriately controlled.
In selected patients, medication plans may include:
- ICS-containing therapy
- Appropriate reliever therapy
- Montelukast in selected cases
- Other preventive measures
32. Why Antibiotics Are Usually Not Asthma Drugs
Asthma is not generally a bacterial infection.
Therefore, antibiotics are not routinely used simply because a patient has asthma symptoms.
An antibiotic may be appropriate if a separate bacterial infection is diagnosed.
GINA 2026 does describe specialist consideration of long-term azithromycin for selected adults with persistent symptomatic asthma despite high-dose ICS-LABA, but this is a specialist add-on strategy, not routine treatment. GINA recommends consideration of antimicrobial resistance, ECG assessment, and other precautions before such therapy.
33. Common Pharmacology Exam Questions
Question 1
Which drug rapidly relieves bronchospasm?
Answer: Salbutamol/albuterol
Question 2
Which class is the foundation of anti-inflammatory asthma treatment?
Answer: Inhaled corticosteroids
Question 3
Which LABA has a rapid onset suitable for certain ICS-formoterol reliever regimens?
Answer: Formoterol
Question 4
Should LABA be used alone in asthma?
Answer: No. It should be used with ICS-containing treatment.
Question 5
Which drug blocks leukotriene receptors?
Answer: Montelukast
Question 6
Which drug targets IgE?
Answer: Omalizumab
Question 7
Which biologic targets IL-5?
Answer: Mepolizumab and reslizumab
Question 8
Which drug targets IL-5 receptor alpha?
Answer: Benralizumab
Question 9
Which biologic targets IL-4 receptor alpha?
Answer: Dupilumab
Question 10
Which biologic targets TSLP?
Answer: Tezepelumab
Question 11
Which inhaled drug blocks muscarinic receptors?
Answer: Tiotropium
Question 12
Which drug is associated with a boxed warning for serious neuropsychiatric effects?
Answer: Montelukast
34. Common Mistakes in Asthma Pharmacology
Mistake 1: Thinking SABA treats the entire disease
SABA relieves bronchoconstriction but does not replace anti-inflammatory controller therapy.
Mistake 2: Using LABA alone
LABA monotherapy is inappropriate for asthma.
Mistake 3: Ignoring inhaler technique
Poor technique can make an effective drug appear ineffective.
Mistake 4: Escalating medication without checking adherence
Before escalating treatment, clinicians should determine whether the patient is actually taking the prescribed medicine.
Mistake 5: Forgetting montelukast's safety warning
Neuropsychiatric adverse effects must be considered.
Mistake 6: Thinking biologics are rescue medications
They are long-term targeted treatments, not emergency bronchodilators.
Mistake 7: Repeatedly using systemic steroids without reassessing asthma control
Frequent oral corticosteroid exposure carries cumulative risks.
35. A Simple Way to Remember Asthma Drugs
Think about asthma pharmacology in five layers:
Layer 1 — Open the airway quickly
SABA
Example:
Salbutamol
Layer 2 — Control inflammation
ICS
Examples:
Budesonide, fluticasone, beclometasone
Layer 3 — Maintain bronchodilation
LABA + ICS
Examples:
Formoterol + budesonide
Salmeterol + fluticasone
Layer 4 — Add additional bronchodilation
LAMA
Example:
Tiotropium
Layer 5 — Target severe inflammatory disease
Biologics
Examples:
Omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab
This framework makes asthma pharmacology much easier to remember.
36. The Most Important Drug Associations
| Drug | Remember it as |
|---|---|
| Salbutamol | Rapid β₂ bronchodilator |
| Formoterol | Rapid-onset LABA |
| Salmeterol | Long-acting bronchodilator |
| Budesonide | ICS |
| Fluticasone | ICS |
| Tiotropium | LAMA |
| Ipratropium | SAMA |
| Montelukast | Leukotriene receptor antagonist |
| Theophylline | Methylxanthine |
| Omalizumab | Anti-IgE |
| Mepolizumab | Anti-IL-5 |
| Benralizumab | Anti-IL-5Rα |
| Dupilumab | Anti-IL-4Rα |
| Tezepelumab | Anti-TSLP |
| Prednisolone | Systemic corticosteroid |
37. A Practical Asthma Medication Decision Framework
When evaluating asthma pharmacotherapy, ask:
Step 1
Does the patient have asthma symptoms and objective evidence supporting the diagnosis?
Step 2
How severe are the current symptoms?
Step 3
Is the patient experiencing an acute exacerbation?
Step 4
Does the current regimen contain an ICS?
Step 5
Is the patient using the inhaler correctly?
Step 6
Is the patient adherent?
Step 7
How frequently is the reliever being used?
Step 8
Are there modifiable triggers?
Step 9
Are there comorbidities?
Step 10
If asthma remains uncontrolled, does the patient need step-up therapy or specialist assessment?
This prevents the common mistake of simply adding another drug without identifying why asthma is uncontrolled.
38. Acute Asthma: Important Warning Signs
A severe asthma attack can become life-threatening.
Urgent medical assessment is required when a patient develops features such as:
- Severe breathlessness
- Difficulty speaking because of breathlessness
- Marked accessory-muscle use
- Cyanosis
- Drowsiness or confusion
- Very poor response to reliever treatment
- Severe or worsening hypoxemia
- Silent chest
- Exhaustion
A silent chest is particularly concerning because extremely severe airflow limitation can produce very little wheezing.
39. Asthma Drugs in Children
Medication selection in children requires special consideration.
Important factors include:
- Age
- Inhaler device
- Ability to coordinate inhalation
- Spacer use
- Growth considerations
- Adherence
- Asthma severity
- Local regulatory approvals
Drug doses and approved ages differ among products.
Therefore, pediatric asthma treatment should follow age-specific guidelines and the individual product information rather than simply applying adult doses.
40. Asthma Treatment Is More Than Medication
Medication is only one part of asthma management.
A comprehensive plan may also involve:
- Smoking avoidance
- Trigger reduction
- Allergy management
- Vaccination where appropriate
- Physical activity
- Weight management where relevant
- Correct inhaler technique
- Written asthma action plan
- Regular follow-up
- Monitoring lung function
- Recognition of exacerbation symptoms
The best asthma medication cannot compensate completely for incorrect inhaler technique or poor adherence.
41. Frequently Asked Questions
Is salbutamol a controller medicine?
Salbutamol is primarily a rapid bronchodilator. It should not be considered a substitute for appropriate ICS-containing asthma treatment.
Is budesonide a bronchodilator?
No.
Budesonide is an inhaled corticosteroid and primarily works by reducing airway inflammation.
Is formoterol a steroid?
No.
Formoterol is a β₂-adrenergic bronchodilator.
When combined with budesonide, the combination contains both:
ICS + LABA
Can LABA be used alone in asthma?
No. LABA should be used as part of ICS-containing treatment.
Is montelukast a steroid?
No.
Montelukast is a leukotriene receptor antagonist.
Is montelukast a rescue medication?
No. It does not replace rapid bronchodilator therapy for an acute attack.
Is theophylline still used?
It can be used in some circumstances, but its role is much more limited because of its narrow therapeutic index and adverse-effect/interactions profile.
Are biologics used for every asthma patient?
No.
They are generally reserved for selected patients with severe asthma who meet specific clinical and/or biomarker criteria despite optimized standard therapy.
Which asthma medication is an anti-IgE drug?
Omalizumab.
Which asthma drugs target IL-5?
Examples include:
Mepolizumab, reslizumab, and benralizumab — although benralizumab targets the IL-5 receptor rather than IL-5 itself.
Which biologic blocks IL-4 and IL-13 signaling?
Dupilumab, through blockade of IL-4 receptor alpha.
Which asthma biologic targets TSLP?
Tezepelumab.
Conclusion
Asthma pharmacology becomes much easier when the medications are organized according to their mechanisms and clinical roles.
SABA such as salbutamol rapidly relax bronchial smooth muscle.
ICS such as budesonide and fluticasone control airway inflammation and form the foundation of anti-inflammatory asthma treatment.
LABAs such as formoterol and salmeterol provide prolonged bronchodilation but should be used with ICS-containing therapy in asthma.
ICS-formoterol has become particularly important because appropriate regimens can combine symptom relief with anti-inflammatory treatment.
LAMA therapy, especially tiotropium, can be added in selected patients whose asthma remains uncontrolled.
Montelukast blocks leukotriene receptors and can be useful in selected patients, but its important neuropsychiatric warning must be remembered.
Systemic corticosteroids remain essential for many significant asthma exacerbations but should not be used unnecessarily because repeated exposure can cause substantial systemic adverse effects.
For severe asthma, modern pharmacology has moved toward precision medicine. Omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, tezepelumab, and other targeted therapies allow clinicians to address specific inflammatory pathways in appropriately selected patients. GINA's 2026 strategy provides the current international framework for these treatment decisions.
The central concept to remember is:
Asthma treatment is not simply about opening the airway. It is about controlling airway inflammation, preventing exacerbations, relieving symptoms, and tailoring treatment to the individual patient's disease phenotype.
.jpeg)
